GET DAILY SIGNALSOneMedNet (ONMD) +32% Rally Driven by Revenue Guidance and Record Bookings
Key Takeaways
- ONMD shares rose roughly 32% over the trailing 30 days, rebounding from an October low near $3.61 to approximately $5.62.
- The advance followed preliminary third-quarter 2026 revenue of about $1 million and fourth-quarter revenue guidance of $12 million to $14 million.
- Year-to-date contracted bookings reached approximately $18.76 million, nearly 14 times full-year 2025 bookings, with about half from new customers.
- Over the trailing quarter, the stock remains lower by roughly 24%, reflecting a volatile multi-month range after a sharp mid-year repricing.
- Investor interest centers on OneMedNet's AI-ready Real-World Data platform, strengthened by its integration of Palantir Foundry.
- For deeper analysis, review ONMD's Price Targets, Earnings, and Forecast on Tickeron's dedicated pages.
- Explore Trending AI Robots to see how AI-driven trading bots approach tickers like ONMD.
Company Background and Market Position
OneMedNet Corporation is a healthcare technology company headquartered in Eden Prairie, Minnesota. Through its flagship iRWD platform, the company curates and delivers regulatory-grade, AI-ready Real-World Data (RWD) to life sciences organizations, medical device manufacturers, contract research organizations, and AI developers. Its datasets integrate de-identified medical imaging with clinical records such as electronic health records, radiology, cardiology, and laboratory data, sourced directly from a federated network of more than 2,300 healthcare provider sites.
OneMedNet positions itself as a "first-party" or direct-from-source data provider, distinguishing its offering from datasets aggregated through intermediaries or secondary markets. This emphasis on sourcing data at the point of care, combined with AI-driven de-identification and curation, supports applications ranging from drug development and regulatory submissions to foundational AI model training. I think investors follow ONMD closely because its growth narrative ties directly to surging demand for high-quality healthcare data used to train and validate AI models. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance Over the Past 30 Days and Quarter
Over the trailing 30 days, ONMD advanced approximately 32%, climbing from a closing price of $4.25 in early October to about $5.62 at the most recent reading. The recovery was especially pronounced in early November, when the shares gained sharply following the company's preliminary revenue update and bookings announcement.
The longer-term picture is more mixed. Over the trailing quarter, ONMD remains down roughly 24%, having traded near $7.44 in mid-August before sliding to an intraday low of $3.61 in mid-October — a level that marked a fresh 52-week low. The subsequent rebound reflects renewed buying interest, but the stock still trades well below its 52-week high of $23.00, underscoring the elevated volatility that has characterized the shares throughout the year.
Drivers Behind the Recent 30-Day Advance
The 30-day advance was driven primarily by a series of positive operational and financial announcements. On November 6, OneMedNet reported preliminary third-quarter 2026 revenue of approximately $1 million, representing a 242% sequential increase from the second quarter and a 465% year-over-year increase. More notably, the company guided to fourth-quarter 2026 revenue of approximately $12 million to $14 million, pending anticipated customer acceptance of delivered data.
Momentum continued when the company disclosed that year-to-date contracted bookings had reached approximately $18.76 million as of November 6 — nearly 14 times full-year 2025 bookings — with roughly half of 2026 contracts originating from new customers. Management framed the update as evidence that its commercial strategy is "working," emphasizing that data curation, de-identification, and delivery infrastructure are now in place to scale with demand. These announcements, coupled with earlier re-orders from a foundation-model customer and additional channel partner agreements, reinforced investor confidence that bookings are beginning to convert into recognized revenue.
Factors Influencing Performance Over the Past Quarter
Over the past quarter, ONMD's trajectory was shaped by a larger narrative of transition and execution. The stock's summer decline reflected investor concerns about a still-unprofitable business model, a relatively high price-to-sales ratio, and the slow conversion of contracted bookings into recognized revenue. Through September 30, only about $1.388 million of the company's expanded bookings had been converted to revenue, a gap that weighed on sentiment and contributed to the October low.
The recovery that followed was anchored by the company's accelerating commercial traction, its deepening integration with Palantir Foundry to enable conversational search across real-time medical data, and management's guidance for a sharp fourth-quarter revenue inflection. The combination of a dramatically reduced debt load, a rapidly expanding provider network, and a growing pipeline of multi-year subscription opportunities has reframed the quarterly story from one of execution risk to one of scaling a recurring-revenue data platform.
Key Elements to Watch in the ONMD Outlook
Looking ahead, the most important variable for ONMD is whether the company can deliver on its fourth-quarter revenue guidance of $12 million to $14 million, which hinges on customer acceptance of data deliveries by quarter-end. The finalized third-quarter 10-Q filing, expected by mid-November, should clarify reported results and any adjustments to the preliminary figures. Investors will also be watching the pace at which the roughly $18.76 million in year-to-date bookings converts into recognized revenue, since a low conversion rate has been a persistent concern.
Beyond financials, the trajectory of the AI-driven healthcare data market, the expansion of the Palantir-powered platform, and the company's ability to add and retain channel partners and foundation-model customers will shape sentiment. Macroeconomic conditions, small-cap funding availability, and continued share-price volatility remain key risks. As with any early-stage, thinly capitalized growth company, near-term outcomes depend heavily on execution rather than valuation support alone. From what I see, this is important because the next few weeks could clarify how quickly the bookings translate into revenue.
Enhancing Research with Automated Strategies
One resource I turn to regularly for additional perspective is Tickeron's Trending AI Robots. It highlights a selection of AI-powered trading bots that monitor thousands of tickers, allowing me to compare how systematic strategies are interpreting current conditions around names like ONMD. This helps round out my own fundamental review without replacing it.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
ONMD in -5.38% downward trend, falling for three consecutive days on October 30, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ONMD declined for three days, in 218 of 241 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
ONMD broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ONMD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ONMD's RSI Indicator exited the oversold zone, 18 of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 35 of 57 cases where ONMD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 61%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ONMD as a result. In 41 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 51%.
The Moving Average Convergence Divergence (MACD) for ONMD just turned positive on October 21, 2026. Looking at past instances where ONMD's MACD turned positive, the stock continued to rise in 30 of 57 cases over the following month. The odds of a continued upward trend are 53%.
ONMD moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +43.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONMD advanced for three days, in 113 of 149 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. ONMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ONMD's P/B Ratio (-86.621) is very low in comparison to the industry average of (4.477). P/E Ratio (-3.024) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. ONMD's P/S Ratio (23.529) is slightly higher than the industry average of (6.065).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement